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a b s t r a c t
Despiteabout twodecadesof research in thefieldof endocrineactivecompounds, still novalidatedhuman
recombinant (hr) estrogen receptor- (ER) binding assay is available, although hr-ER is available from
several sources. In a joint effort, US EPA and Bayer Schering Pharma with funding from the EU-sponsored
6th framework project, ReProTect, developed a model protocol for such a binding assay. Important fea-
tures of this assay are the use of a full length hr-ER and performance in a 96-well plate format. A
full length hr-ER was chosen, as it was considered to provide the most accurate and human-relevant
results,whereas truncated receptors couldperformdifferently. Besides three reference compounds [17-
estradiol, norethynodrel, dibutylphthalate] nine test compounds with different affinities for the ER
[diethylstilbestrol (DES), ethynylestradiol, meso-hexestrol, equol, genistein, o,p′-DDT, nonylphenol, n-
butylparaben, and corticosterone] were used to explore the performance of the assay. Three independent
experiments per compound were performed on different days, and dilutions of test compounds from
deep-frozen stocks, solutions of radiolabeled ligand and receptor preparation were freshly prepared for
each experiment. The ER binding properties of reference and test compounds were well detected. As
expected dibutylphthalate and corticosterone were non-binders in this assay. In terms of the relative
ranking of binding affinities, there was good agreement with published data obtained from experiments
using a human recombinant ER ligand binding domain. Irrespective of the chemical nature of the com-
pound, individual IC50-values for a given compound varied by not more than a factor of 2.5. Our data
demonstrate that the assay was robust and reliably ranked compounds with strong, weak, and no affin-
ity for the ER with high accuracy. It avoids the manipulation and use of animals, i.e., the preparation
of uterine cytosol as receptor source from ovariectomized rats, as a recombinant protein is used and
thus contributes to the 3R concept (reduce, replace, and refine). Furthermore, in contrast to other assays,
this assay could be adjusted to an intermediate/high throughput format. On the whole, this assay is a
promising candidate for further validation.
© 2010 Elsevier Inc. All rights reserved.
1. Introduction
There is concern that man-made and natural compounds may
interfere with the endocrine system and thus may affect wildlife
and humans and/or their progeny. Initial studies focused on inter-
actions with estrogen receptor (ER)-mediated signaling and date
back to the 1980s [see 1]. These studies have intensified over the
years and have been used to characterize a number of chemicals
and natural products as compounds with weak estrogenic proper-
∗ Corresponding author. Tel.: +49 202 36 8832; fax: +49 202 36 4137.
E-mail address: alexius.freyberger@bayerhealthcare.com (A. Freyberger).
ties. More recently, interactions with other receptors such as the
androgen receptor have gained attention [2–4]. Both the recom-
mendations to the US Environmental Protection Agency (EPA) by
their Endocrine Disruptor Screening and Testing Advisory Com-
mittee (EDSTAC) [5] and the OECD conceptual framework for
the testing and assessment of endocrine disrupting chemicals [6]
recognized receptor binding assays as important tools to study
interactions with sex hormone receptors. These assays, therefore,
represent important components of the US EPA tier 1 screening
battery and level 2 of the OECD’s conceptual framework. Interest-
ingly, despite two decades of research in the field of endocrine
active compounds and the availability of human recombinant ER
from several sources, no validated human recombinant ER bind-
0890-6238/$ – see front matter © 2010 Elsevier Inc. All rights reserved.
doi:10.1016/j.reprotox.2010.01.001
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ing assay is available. In a joint effort, US EPA and Bayer Schering
Pharma (BSP) (with funding from the European Union-sponsored
6th framework project, ReProTect), developed a model protocol.
Additional advisement to this activity was given from an inter-
national expert group working on the validation of recombinant
ER and AR binding assays under the auspices of the OECD’s Val-
idation Management Group for Non-Animal Testing (VMG-NA).
Important features of the protocol for competitive binding stud-
ies were the use of (a) a commercially available full length human
recombinant (hr) estrogen receptor- (ER), (b) [3H]--estradiol
(1nM) as ligand, (c) an amount of ER resulting in a specific bind-
ing corresponding to approximately 20±5% relative to the added
[3H]-ligand, and (d) a 96-well plate format that allows feasibil-
ity for up to nine chemicals to be tested at a time (not including
the reference chemicals). A full length hr-ER was chosen, as it
was considered to provide the most accurate and human-relevant
results, whereas as truncated receptor could perform in a different
manner. A commercially available full length hr-ER was consid-
eredhelpful for peoplenot experienced in the isolationof receptors,
not having the equipment to grow (human) cells prior to isolation,
or that do not want to use animals for the preparation of receptors.
A set of reference (17-estradiol, a strong binder; norethynodrel,
a weak binder; and dibutylphthalate, a non-binder) and test com-
pounds (diethylstilbestrol (DES), ethynylestradiol,meso-hexestrol,
equol, genistein, o,p′-DDT, nonylphenol, n-butylparaben, and cor-
ticosterone) that had been agreed upon by a Chemical Advisory
Board (CAB) jointly appointed by the hr-ER binding assay valida-
tion working group of the OECD’s VMG-NA (see above) was used
to explore the performance of the assay by evaluating a variety of
chemical classes and differing affinities for the receptor. Results
were subjected to an independent statistical analysis. The outcome
of this effort is reported herein.
2. Materials and methods
2.1. Estrogen receptor-˛
Full length human recombinant estrogen receptor- was obtained from Invit-
rogen Corporation (Carlsbad, CA, USA) (order no. P2187, lot no. 34216I). Functional
receptor concentration according to the manufacturer was 2088pmol/mL with a
specific activity of 8700pmol/mg. The receptor preparation was slowly thawed on
ice, and aliquots (20pmol receptor) were placed in microvials, rapidly frozen in
liquid nitrogen and kept deep-frozen at −80 ◦C. Aliquots were thawed only once.
2.2. Chemicals
17ß-Estradiol (CAS 50-28-2) 98%, 17-ethynylestradiol (57-63-6) 98%, diethyl-
stilbestrol (DES, 56-53-1) 99%, m-hexestrol (84-16-2) 98%, dibutylphthalate,
dl-dithiothreitol (DTT) >99%, leupeptin semi-sulfate, bovine serum albumin (BSA),
and dextran-coated charcoal was supplied by Sigma–Aldrich (Taufkirchen, Ger-
many). Nonylphenol (84852-15-3) 96.9% and corticosterone (50-22-6) 98.5% were
obtained from Fluka (Buchs, Switzerland) through Sigma–Aldrich. Racemic equol
(531-95-3) 98.2% was delivered by Apin Chemicals (Abingdon, UK), 1,1,1-trichloro-
2,2-bis(o,p′-chlorophenyl)ethane (o,p′-DDT, 789-02-6) 99.2% was purchased from
Supelco (Bellefonte, PA, USA) through Sigma–Aldrich. Norethynodrel (68-23-5,
United States Pharmacopial Convention) 100%, genistein (446-72-0, American
Custom Chemical Corp.) 99.16%, and n-butylparaben (94-26-8, ChemService)
98.2% were kindly provided by U.S. EPA. Tris(hydroxymethyl)aminomethane p.a.,
anhydrous glycerol, ethanol p.a. and DMSO p.a. were supplied by E. Merck (Darm-
stadt, Germany). Ultima Flo APTM and Ultima Gold scintillation cocktails were
products of Canberra-Packard (Frankfurt, Germany). [3H]-17-estradiol (estradiol
[2,4,6,7,16,17-3H(N)], specific activity: 4.07TBq/mmol, 37MBq/mL) in ethanol
with a radiochemical purity of >97% was supplied by PerkinElmer (Rodgau-
Jürgesheim, Germany).
2.3. Determination of receptor binding
Receptor binding experiments were performed in 96-well microtiter plates in
at least triplicate incubations. Assay buffer (0.2mM leupeptin, 2mmol DTT, 10g
BSA and 100mL glycerol made up to 1 L with 10mM Tris–HCl; pH 7.5) was freshly
prepared for each experiment prior to incubation. Stock solutions of reference
compounds 17-estradiol (10mM), norethynodrel (10mM), and dibutylphthalate
(100mM) and test compounds (100mM)were prepared in ethanol, if 100mMcould
not be achieved, DMSO was used, also for the determination of concurrent total and
non-specific binding. Aliquots of stock solutions were kept deep-frozen at −80 ◦C,
and each aliquotwas used only once anddiscarded at the end of an individual exper-
iment. Serial dilutions of stocks in solvent were made, then diluted into assay buffer
1:50 as the final step. [3H]-ligand solution (4nM if not otherwise indicated result-
ing in a final concentration of 1nM) was prepared in assay buffer. Similarly ERwas
dissolved in assay buffer. To study receptor binding, assay buffer (80L) contain-
ing test compound or solvent (2%) was mixed with 40L [3H]-ligand solution for
10–15min at 2–8 ◦C. Then, 40L of ER solution was added and the whole mixture
was incubated at 2–8 ◦C overnight under slight (appr. 250 rpm) continuous shaking.
Following incubation overnight, 80L of a 5% dextran-coated charcoal suspension
(the optimal percentage had been empirically determined) in cold assay buffer was
added. After mixing in the cold at 2–8 ◦C for 10min, charcoal was sedimented by
centrifugation at 4000 rpm for 5min in a cooling centrifuge at 4 ◦C. Finally, 50L
aliquots of the clear supernatant containing the ER-ligand complex were placed in
another 96-well plate and mixed with 200L Ultima Flo APTM scintillation cocktail
(Canberra-Packard, Frankfurt, Germany) and radioactivity was determined by LSC
usingaLSCmicroplate reader (1450MicrobetaTM Trilux,Wallac, Freiburg,Germany).
In all studies, the actual amount of ligand was determined by liquid scintilla-
tion counting (LSC) in a -counter (1900 TR Counter, Canberra-Packard, Frankfurt,
Germany) with quench correction. The maximally tolerated deviation from the the-
oretical amount was 6%. If the tolerance was exceeded, depending on the deviation,
small volumes of buffer or small amounts of radiolabeled ligandwere added tomeet
the limits.
The amount of receptor as specified in the model protocol should result in a
specific binding roughly corresponding to 20±5% relative to the added labeled
ligand under conditions of competitive binding, however, slight deviations would
be acceptable if not occurring regularly. Furthermore, non-specific binding under
these conditions should not exceed 35% of total binding. To determine the amount
of receptor necessary experimentally, final concentrations of 0.25, 0.5, 0.75, and
1.0nM ER were incubated with 1nM [3H]-17-estradiol, and non-specific bind-
ing was determined in parallel in the presence of 1M radioinert ligand. For each
condition six replicates were performed.
Saturation of the receptor was studied by incubating the receptor with
increasing final concentrations (0.03, 0.06, 0.08, 0.10, 0.30, 0.60, 1.0, 3.0nM) of [3H]-
17-estradiol. Non-specific binding was determined in parallel in the presence of a
1000-fold molar excess of unlabeled 17-estradiol. All incubations were performed
in triplicate.
Studies on competitive binding were performed using a ligand concentration of
1nM [3H]-17-estradiol and had to be spread across several 96-well plates. On
the first plate, ER was incubated with the reference compounds 17-estradiol
(0.010, 0.10, 0.30, 1.0, 3.0, 10, 100, 1000nM), norethynodrel (3.0, 30, 100, 300, 1000,
3000, 10,000, 30,000nM), and dibutylphthalate (0.1, 1.0, 10, 100, 1000, 10×103,
100×103, 1000×103 nM); furthermore, vehicle controls (no competitor), buffer
controls (no competitor, no solvent) and incubations for non-specific binding in the
presence of 1M unlabeled 17-estradiol were performed. On the other plates, the
receptor was incubated with test compounds up to 1mM (0.1, 1.0, 10, 100, 1000,
10×103, 100×103, 1000×103 nM), if possible.
In the course of this investigation, for each reference/test compound four inde-
pendent competitive binding experiments (runs A–D) were performed. For solvent
controls, buffer controls, and non-specific binding six replicates were performed
each, incubations containing reference/test compounds were studied in triplicate.
Run D is the repetition of run C which was invalidated. The statistical analysis for
run C had consistently indicated a putative data error for all 12 compounds under
investigation, and in the light of a ligand concentration of 1nM the IC50-value for
estradiol of 0.08nM was implausibly low.
2.4. Data handling
Using the data analysis program, Prism5.02 (GraphPad Software, Inc., SanDiego,
CA), a user defined analysis titled “One site−Total +Non-Specific (NS) Binding,
accounting for ligand depletion” was performed and entered into Prism tem-
plates for all saturation binding runs. More information on the equation used
is available from the book by Motulsky and Christopoulos (2003), “Fitting mod-
els to biological data using linear and non-linear regression: a practical guide
to curve fitting” GraphPad Software, Inc., San Diego, CA. Available online at:
http://www.graphpad.com/manuals/prism4/RegressionBook.pdf—page 210.
For competitive binding experiments, prior to fitting a dose-response model
and estimation of IC50-values mean non-specific binding was subtracted from bind-
ing observed for solvent and buffer controls or in the presence of reference/test
compounds to achieve the specific binding After subtraction specific binding in the
presence of reference/test compounds was divided by the mean specific binding of
the solvent control. The three-parametric log-logistic function
f (x) = 1
1 + exp(2(log(x) − 3))
was fitted to the transformed data using the drm function of R-package drc [7,8].
Parameter 1 is the upper asymptote of the response range and corresponds to
what is called “Top” in GraphPad Prism, parameter 2 is the slope parameter, and
parameter 3 corresponds to the log of the IC50. Note that there is no estimation
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Fig. 1. Determination of the necessary receptor concentration–linear relationship
between specific binding and receptor concentration. Under conditions correspond-
ing to competitive binding increasing ER concentrationswere incubatedwith 1nM
[3H]-17-estradiol. Non-specific binding was assessed in parallel in the presence
of 1M unlabeled 17-estradiol. Following incubation overnight, unbound radio-
labeled ligand was removed by absorption to dextran-bound charcoal (DBC) and
sedimentation of DBC by centrifugation. ER-bound radiolabel in the supernatant
was determined by liquid scintillation counting. Specific binding was calculated as
the difference of total and non-specific binding. For each condition six replicates
were performed. Means± S.D. are given.
of the lower asymptote of the response range. The “Bottom” was assumed to be 0
after correction for non-specific binding in case of full displacement of ligand from
the receptor. In the context of receptor binding assays, the IC50-value represents
the concentration of a test compound displacing 50% of receptor bound ligand. IC50-
values and95%confidence intervalswere calculatedusing theED functionofpackage
drc. This software programwas also used to generate graphs of competitive binding
experiments.
3. Results
3.1. Determination of the necessary amount of receptor
The model protocol requested an amount of receptor result-
ing in a specific binding corresponding to 20±5% of the added
ligand under conditions of competitive binding (i.e., 1 nM [3H]-
17-estradiol). When increasing amounts of estrogen receptor-
were incubated with 1nM [3H]-17-estradiol in the absence and
presence of unlabeled 1M 17-estradiol (to assess non-specific
binding), a linear relationship between total and specific bind-
ing and receptor concentration was obtained. Non-specific binding
was similar irrespective of the receptor concentration (Fig. 1). The
optimal range used for the following studies was at a receptor con-
centration of 0.5nM, concomitant specific binding corresponding
to 23.1% of the added ligand (Table 1).
3.2. Saturation of estrogen receptor-˛ binding
To characterize the functionality of the receptor, satura-
tion experiments were performed. Receptor was incubated with
increasing concentrations of [3H]-17-estradiol, non-specific bind-
ing was assessed in the presence of 1000-fold molar excess of
Fig. 2. (A) Saturation binding data of the human recombinant full length estrogen
receptor-utilizing [3H]-17-estradiol. ER (nominally 0.5nM)was incubatedwith
increasing final concentrations (0.03, 0.06, 0.08, 0.10, 0.30, 0.60, 1.0, 3.0nM) of [3H]-
17-estradiol (1nM=39,072dpm). Non-specific bindingwas determined in parallel
in thepresenceof a 1000-foldmolar excess of unlabeled17-estradiol. For each con-
dition three replicates were performed. Following incubation overnight, unbound
radiolabeled ligand was removed by absorption to dextran-bound charcoal (DBC)
and sedimentation of DBC by centrifugation. Receptor-bound radiolabeled ligand
in the supernatant was determined by liquid scintillation counting. Specific bind-
ing was calculated as the difference of total and non-specific binding Graphs were
generated using the non-linear regression software program Prism version 5.02.
The figure shows a representative experiment. (B) Scatchard analysis of the human
recombinant full length estrogen receptor- utilizing [3H]-17-estradiol. Data for
total and non-specific binding shown in (A) were analysed by Prism version 5.02
taking into account ligand depletion. The figure shows a representative experiment.
unlabeled 17-estradiol. Non-specific binding increased linearly
andmoderately in relation to the [3H]-17-estradiol concentration,
whereas total binding increased strongly and almost linearly up to
0.6nM [3H]-17-estradiol. At higher concentrations of [3H]-17-
estradiol total binding was still rising, but at a slower rate. Specific
binding increased strongly and almost linearly up to 0.6nM [3H]-
17-estradiol, but at higher concentrations approached a plateau.
These findings correspond well with a fully functional receptor
showing saturable binding at higher ligand concentrations (Fig. 2).
Results of the Scatchard analysis of the saturation experiments are
given in Table 2. The observed mean Kd of 0.3734nM is in the
reported range for the human ER (see also Section 4), and the
Bmax of 0.3439nM corresponds well to the added receptor con-
centration of 0.5nM.
Table 1
Determination of the necessary receptor concentration.
Receptor concentration (nominal) [nM] Mean specific binding (total incubation) [dpm] Specific binding (relative to the nominally added ligand) [%]
0.25 4,874 12.5
0.50 9,029 23.1
0.75 12,635 32.3
1.00 16,151 41.3
The assay was performed under conditions corresponding to competitive binding, i.e., in the presence of 1nM [3H]-17-estradiol (nominally 39,072dpm) and increasing ER
concentrations as indicated. Non-specific binding was assessed in parallel incubations containing 1M unlabeled 17-estradiol. Following incubation overnight, unbound
radiolabeled ligand was removed by absorption to dextran-bound charcoal (DBC) and sedimentation of DBC by centrifugation. Receptor-bound radiolabeled ligand in the
supernatant was determined by liquid scintillation counting. Specific binding was calculated as the difference of total and non-specific binding. For each condition six
replicates were performed.
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Table 2
Scatchard analysis of saturation experiments.
Experiment No. Kd [nM] Bmax [nM]
1 0.3822 0.3533
2 0.3851 0.2992
3 0.3530 0.3791
Mean± S.D. 0.3734±0.0178 0.3439±0.0408
ERwas incubated with increasing final concentrations (0.03, 0.06, 0.08, 0.10, 0.30,
0.60, 1.0, 3.0nM) of [3H]-17-estradiol. Non-specific binding was determined in
parallel in the presence of a 1000-fold molar excess of unlabeled 17-estradiol. For
each condition three replicates were performed. Following incubation overnight,
unbound radiolabeled ligandwas removedbyabsorption todextran-boundcharcoal
(DBC) and sedimentation of DBC by centrifugation. Receptor-bound radiolabeled
ligand in the supernatant was determined by liquid scintillation counting. Three
independent experiments were run. Scatchard analysis was performed using Graph
Pad Prism 5.02 taking into account ligand depletion.
3.3. Competition experiments
General binding characteristics in the absence of competitor are
summarized in Table 3. In the presence of optimal ligand con-
centrations (99–101% of the nominal value) little variability for
total, non-specific and specific bindings was observed across the
experiments. Specific binding for vehicle controls corresponded
to 22.6–29.8% of the theoretically added ligand, the correspond-
ing coefficient of variation across the six experiments was 12.2%.
Similar figures were obtained for specific binding for buffer con-
trols (total binding in the absence of solvent minus non-specific
binding), however, there seemed to be a trend to higher values for
specific binding in DMSO controls compared to specific binding in
buffer controls. Mean non-specific binding corresponded to 15% of
total binding, accordingly, total bindingmostly represented specific
binding to the receptor.
Standard solvent was ethanol, and with the exception of 17-
estradiol and norethynodrel, all compounds were considered for
testing up to 1mM, an aim that could not always be achieved.
A final concentration of 1mM resulted in strong turbidity for
dibutylphthalate, DES, and ethynylestradiol, and in slight turbid-
ity for m-hexestrol and nonylphenol. Genistein and corticosterone
could only be tested up to 100M (final conc.) due to their lim-
ited solubility in ethanol, whereas 100M o,p′-DDT still resulted
in turbidity. In order to potentially improve their solubility, genis-
tein, o,p′-DDT, and corticosterone togetherwith the set of reference
Table 3
Receptor binding characteristics in competition experiments in the absence of competitor.
Experiment Solvent Ligand concentration
[% of nominal]
Binding [% of nominally added ligand]
Total Non-specific Specific
Buffer Solvent Buffer Solvent
A Ethanol 100.6 30.75 30.33 4.35 26.40 25.98
B Ethanol 99.9 26.88 27.86 4.02 22.86 23.85
D Ethanol 100.2 34.76 35.01 5.26 29.50 29.75
E DMSO 99.1 24.21 26.33 3.71 20.50 22.62
F DMSO 101.3 23.43 27.70 4.55 18.88 23.15
G DMSO 99.3 29.18 33.77 4.34 24.84 29.43
ERwas incubated with 1.0nM of [3H]-17-estradiol in the presence or absence of 1% solvent as indicated. Non-specific binding was determined in parallel in the presence
of 1M unlabeled 17-estradiol. For each condition six replicates were performed. Following incubation overnight, unbound radiolabeled ligand was removed by absorption
to dextran-bound charcoal (DBC) and sedimentation of DBC by centrifugation. Receptor-bound radiolabeled ligand in the supernatant was determined by liquid scintillation
counting. Three independent experiments were run for each solvent. Specific binding was calculated as the difference of total and non-specific binding. Corresponding mean
values are given.
Fig. 3. Competitive binding to the human recombinant full length estrogen receptor- of reference and test compounds using ethanol as solvent. Receptor (nominally 0.5nM)
was incubated with 1nM [3H]-17-estradiol and increasing concentrations of compounds as indicated. Following incubation overnight, unbound radiolabeled ligand was
removed by absorption to dextran-bound charcoal (DBC) and sedimentation of DBC by centrifugation. Receptor-bound radiolabeled ligand in the supernatantwas determined
by liquid scintillation counting. Binding was corrected for non-specific binding (NSB) and expressed relative to the corresponding solvent control. For the solvent control and
for NSB in the presence of 1M 17-estradiol six replicates were performed, any other condition was studied in triplicate. Data correspond to run D. For the sake of clarity,
only the curve fit, but no individual data points are given.
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Fig. 4. Competitive binding to the human recombinant full length estrogen
receptor- of reference and test compounds using DMSO as solvent. Receptor
(nominally 0.5nM)was incubatedwith1nM[3H]-17-estradiol and increasing con-
centrations of compounds as indicated. Following incubation overnight, unbound
radiolabeled ligand was removed by absorption to dextran-bound charcoal (DBC)
and sedimentation of DBC by centrifugation. Receptor-bound radiolabeled ligand in
the supernatant was determined by liquid scintillation counting. Binding was cor-
rected for non-specific binding (NSB) and expressed relative to the corresponding
solvent control. Data correspond to run D. For the solvent control and for NSB in the
presence of 1M 17-estradiol six replicates were performed, any other condition
was studied in triplicate. Data correspond to run F. For the sake of clarity, only the
curve fit, but no individual data points are given.
compoundswere also testedusingDMSOas solvent. Corticosterone
and genistein could be dissolved in DMSO at 100mM, but the
resulting final concentration of 1mMresulted in slight turbidity for
genistein. Similarly, final concentrations of 1mM dibutylphtalate
and 100M o,p′-DDT resulted in strong and slight (o,p′-DDT) tur-
bidity. Accordingly, only for corticosterone the use of DMSO finally
resulted in an improved solubility.
ER binding data for all compounds dissolved in ethanol
expressed as IC50-values are summarized in Table 4. Irrespective
of limited solubility in ethanol or in the final assay, IC50-values
could be observed for all reference and test compounds except for
dibutylphthalate and corticosterone that showed no affinity to the
ER. A compilation of representative displacement curves using
ethanol as solvent is shown in Fig. 3. Corresponding relativebinding
affinities (IC50 of 17-estradiol divided by the IC50 of the test chem-
ical andmultiplied by 100) are given in Table 5. Genistein, o,p′-DDT,
and corticosterone together with the set of reference compounds
were also tested using DMSO as solvent. A compilation of repre-
sentative displacement curves using DMSO as solvent is given in
Fig. 4. Corresponding IC50-values and relative binding affinities are
presented in Tables 6 and 7.
Overall, the following rank order of affinity to the ER could be
established:
17-Estradiol > ethynylestradiol >DES>m-hexestrol > equol >
norethynyodrel > genistein≈nonylphenol > o,p′-
DDT>butylparaben
Dibutylphthalate and corticosteronewere characterized as non-
binders. The observed rank order of affinity to the ER was in line
with our expectations.
4. Discussion
The value of receptor binding assays both as a mechanistic tool
to characterize receptor mediated endocrine activity, but also as an
important screening assay for endocrine active compounds, is well
recognized. Interestingly, after two decades of research in the field
of endocrine active compounds, still no validated human recombi-
nant (full length) ER binding assay is available. Aim of this work
was to evaluate amodel protocol as a first step towards a validation
of a human recombinant full length ER binding assay.
The model protocol worked well and the general requirements
were fulfilled: non-specific binding in competition experiments
was clearly below the maximally tolerated 35% of total binding
and specific binding roughly corresponded to 20±5% relative to
the added [3H]-17-estradiol for solvent controls. The upper limit
was occasionally slightly exceeded, but not on a regular basis
and thus was acceptable. Saturation experiments demonstrated
that at a ligand concentration of 1nM binding the receptor was
still not saturated. This indicates that on the one hand competi-
tors could readily displace [3H]-17-estradiol from the ER, and
on the other hand the ligand concentration was high enough to
provide a readily measurable signal. Scatchard analysis of the sat-
uration experiments provided a mean Kd of 0.3734nM which is
well within the range of reported Kd values for full length human
recombinant ER or ER isolated from human cells, whereas trun-
cated recombinant ER andpossibly rat uterineERmayhavehigher
Kd values (see Table 8). The observed Bmax of 0.3439nM corre-
sponds well to the added 0.5nM receptor protein (determined by
means of the hydroxyapatite methodology according to the man-
ufacturer’s information) and indicates equivalence of the charcoal
and hydroxyapatite methodologies.
When competitive binding was studied, irrespective of the
chemical nature of the compound and the solvent used, for a given
compound individual IC50-values varied by not more than a fac-
tor of 2.5 from one another. Variability of binding affinities relative
to 17-estradiol (RBA) was in the same range, only for equol (2.9)
and genistein (3.3) slightly higher values were observed. In general
IC50-values for runs A and B were more comparable to each other
than data from run D. However, there was no uniform trend, and
IC50-values obtained in run D were either higher, lower, or com-
parable (n-butylparaben) to those in the other runs. No difference
in the quality of the data sets for run D was observed and IC50-
values for run D maximally differed from those of runs A and B by
a factor of 2.2. This difference – in the absence of a trend – was
considered as random. Mean coefficients of variation (CVs) across
all compounds were 25% (ethanol as solvent) and 13% (DMSO) for
IC50-values and 24% (ethanol) and 13% (DMSO) for relative binding
affinities. These low values, especially in light of the low number
of independent experiments, indicate that the assay is capable of
accurately assessing receptor affinities with only small variability.
Following an ICCVAM/NICEATM recommendation [9] ethanol
was used as solvent whenever possible. Accordingly, only few
compounds, namely the reference compounds 17-estradiol,
norethynodrel, and dibutylphthalate as well as genistein, o,p′-DDT,
and corticosterone were tested using both solvents. The use of
DMSO seemed to provide lower variability of the IC50/RBA val-
ues and possibly slightly lower IC50-values compared to the use
of ethanol. However, in the light of the low number of experiments
with DMSO and the small number of compounds studied, it is cur-
rently not possible to consider one solvent more appropriate than
the other. Basically, both solvents can be used with the assay, and
these options can be helpful to achieve optimal dissolution of test
compounds.
Optimal interactions of a ligand with its receptor requires that
the free ligand concentration is similar to the added concentra-
tion, i.e., total binding as the sum of specific and non-specific
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Table 4
IC50-values achieved for reference and test compounds using ethanol as solvent.
Compound Experiment IC50-value [nM] Confidence interval [nM] Coefficient of variation [%]
Lower Upper
17-Estradiol A 1.297 1.1800 1.425
B 1.301 1.1880 1.425
D 0.965 0.8814 1.057
Mean± S.D. 1.188±0.193 16.2
Norethynodrel A 451.2 408.2 498.6
B 410.8 366.1 460.8
D 702.3 623.9 790.6
Mean± S.D. 521.4±157.9 30.3
Dibutylphthalate A No affinitya
B No affinity
D No affinity
Mean± S.D. – –
17-Ethynylestradiol A 1.939 1.673 2.246
B 2.508 1.930 3.259
D 1.294 1.199 1.397
Mean± S.D. 1.914±0.607 31.7
DES A 7.961 6.980 9.081
B 7.723 6.611 9.021
D 5.550 4.931 6.247
Mean± S.D. 7.078±1.329 18.8
m-Hexestrol A 34.62 30.58 39.18
B 36.07 20.39 63.81
D 16.02 13.16 19.50
Mean± S.D. 28.90±11.18 38.7
Equol, racemic A 93.78 75.03 117.2
B 91.09 67.00 123.8
D 197.2 180.0 216.0
Mean± S.D. 127.4±60.50 47.5
Genistein A 422.6 350.2 509.9
B –b – –
D 1049 788.8 1394
Mean 735.8 Not calculated
Nonylphenol A 868.8 628.7 1201
B 1024 692.6 1514
D 859.8 589.2 1255
Mean± S.D. 917.5±92.3 10.1
o,p′-DDT A –b – –
B 1333 950.0 1872
D 2399 1937 2970
Mean 1866 Not calculated
n-Butylparaben A 228.4×102 166.6×102 313.1×102
B 254.0×102 183.0×102 352.7×102
D 232.0×102 162.0×102 332.4×102
Mean± S.D. 238.1×102 ±13.85×102 5.8
Corticosterone A No affinitya
B No affinity
D No affinity
Mean± S.D. – –
ER (nominally 0.5nM) was incubated with 1nM [3H]-17-estradiol and increasing concentrations of the indicated compounds. Following incubation overnight, unbound
radiolabeled ligand was removed by absorption to dextran-bound charcoal (DBC) and sedimentation of DBC by centrifugation. ER-bound radiolabel in the supernatant was
determined by liquid scintillation counting. Binding was corrected for non-specific binding (NSB) and expressed relative to the corresponding solvent control. For the solvent
control and NSB in the presence of 1M 17-estradiol six replicates were performed, any other condition was studied in triplicate. IC50-values were calculated by means of
the software R-package drc using a three-parametric log-logistic function. Results from three independent experiments A, B, and D are given.
a Dibutylphthalate and corticosterone were tested up to 100M.
b No IC50-value was calculated due to unclear dose response (displacement curves were comparable to corresponding experiments, but contained one or two aberrant
data points a low concentrations).
binding should not exceed 10%. However, assay miniaturization
in order to allow intermediate or high throughput, increases the
risk of ligand depletion (where the actual free ligand concentration
is significantly lower than the added ligand concentration), since
receptor concentrations are rather high in these assays in order to
achieve adequate signal sizes [10]. In competition experiments, lig-
and depletion results in a shift of competition curves/IC50-values
to the right, i.e., to higher concentrations [11]. With regard to the
experiments reported herein, total binding in vehicle controls of
competition experiments corresponded to 26–35%of the added lig-
and (see Table 3). Thus, in all experiments slight ligand depletion
had occurred. Modeling of ligand depletion [11] indicated that the
impact on competition experiments of a depletion up to 38% was
small. Accordingly, competition experiments reported herein was
sufficiently accurate in terms of ligand depletion and no corrective
action is needed. The use of relative binding affinities with all com-
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Table 5
Relative binding affinities for reference and test compounds using ethanol as solvent.
Compound Experiment No. Relative binding affinity [%] Coefficient of variation [%]
17-Estradiol 100 –
Norethynodrel A 0.2875
B 0.3167
D 0.1374
Mean± S.D. 0.2472±0.0962 38.9
Dibutylphthalate A No affinity
B No affinity
D No affinity
Mean± S.D. – –
17-Ethynylestradiol A 66.89
B 51.87
D 74.57
Mean± S.D. 64.45±11.55 17.9
DES A 16.29
B 16.85
D 17.39
Mean± S.D. 16.84±0.55 3.3
m-Hexestrol A 3.746
B 3.607
D 6.024
Mean± S.D. 4.459±1.357 30.4
Equol, racemic A 1.383
B 1.428
D 0.489
Mean± S.D. 1.100±0.530 48.2
Genistein A 0.3069
B –
D 0.0920
Mean 0.1995 Not calculated
Nonylphenol A 0.1493
B 0.1271
D 0.1122
Mean± S.D. 0.1295±0.0186 14.4
o,p′-DDT A –
B 0.0976
D 0.0402
Mean 0.0689 Not calculated
n-Butylparaben A 0.00568
B 0.00512
D 0.00416
Mean± S.D. 0.00499±0.00077 15.4
Corticosterone A No affinity
B No affinity
D No affinity
Mean± S.D. – –
Relative binding affinities were calculated from data given in Table 4.
poundsbeing testedunder the sameconditions should even further
minimize a small impact of ligand depletion.
An important step in the evaluation of an assay is the compar-
ison of assay data with data from similar assays observed for the
same test compounds. In Table 9, results from the investigation
reported herein are compared to ER binding data from several
sources. With regard to data generated for full length human
recombinant ER [12,13] and for a human recombinant ER ligand
binding domain as receptor source (by the Chemicals Evaluation
and Research Center (CERI) in Japan with funding by the Japanese
Ministry of Economy, Trade and Industry [14]), a good to very good
fit for the binding relative to estradiol (RBA) was observed. For
compounds with weak affinity to the ER the concurrence was
excellent, and also for compounds with stronger affinity, the rank-
ing was comparable, although in absolute terms in our hands the
relative binding values for DES, ethynylestradiol and m-hexestrol
were lower mainly compared to the CERI data. A similar constella-
tion was observed when comparing our RBAs with those observed
for rat uterine cytosol as receptor source [15,16]. It remains to be
elucidated further whether these lower RBAs are characteristic of
the human recombinant full length ER as opposed to a human
truncated or rat receptor or are related to other reasons such as the
solvent used or assay buffer composition (e.g., in aqueous media
DES can be converted to its much weaker cis-isomer). If this was
the case for a large portion of DES, the lower RBA of DES could read-
ily be explained [17]. The CERI assay utilizedDMSOas the solvent in
all experiments, while this assay used EtOH as the solvent for DES.
Finally, as reported here and by others [14,15], dibutylphthalate
and corticosterone did not show affinity for the ER.
On the whole, our data demonstrate that the assay was robust
and reliably ranked compounds with strong, weak, and without
affinity for the ER with high accuracy. Using a human recombi-
nant full length estrogen receptor-, it avoids the manipulation
and use of animals, i.e., the preparation of uterine cytosol from
ovariectomized rats, and thus contributes to the 3R concept. Fur-
thermore, in contrast to other assays, our assay could be adjusted
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Table 6
IC50-values achieved for reference and test compounds using dimethylsulfoxide as solvent.
Compound Experiment No. IC50-value [nM] Confidence interval [nM] Coefficient of variation [%]
Lower Upper
17-Estradiol E 0.9857 0.8443 1.151
F 0.8193 0.7280 0.9220
G 0.7654 0.6624 0.8845
Mean± S.D. 0.8568±0.1148 13.4
Norethynodrel E 424.5 384.5 468.8
F 353.4 308.9 404.4
G 365.5 298.6 447.4
Mean± S.D. 381.1±38.0 10.0
Dibutylphthalate E No affinitya
F No affinity
G No affinity
Mean± S.D. – –
Genistein E 744.5 611.3 906.6
F 776.4 678.6 888.4
G 633.1 520.1 770.7
Mean± S.D. 718.0±75.2 10.5.
o,p′-DDT E 1405 1081 1825
F 1770 1339 2340
G 1225 923.6 1625
Mean± S.D. 1467±278 19.0
Corticosterone E No affinitya
F No affinity
G No affinity
Mean± S.D. – –
ER (nominally 0.5nM) was incubated with 1nM [3H]-17-estradiol and increasing concentrations of the indicated compounds. Following incubation overnight, unbound
radiolabeled ligand was removed by absorption to dextran-bound charcoal (DBC) and sedimentation of DBC by centrifugation. ER-bound radiolabel in the supernatant was
determined by liquid scintillation counting. Binding was corrected for non-specific binding (NSB) and expressed relative to the corresponding solvent control. For the solvent
control and NSB in the presence of 1M 17-estradiol six replicates were performed, any other condition was studied in triplicate. IC50-values were calculated by means of
the software R-package drc using a three-parametric log-logistic function. Results from three independent experiments E, F, and G are given.
a Dibutylphthalate was tested up to 100M, corticosterone up to 1mM.
to an intermediate/high throughput format. In terms of the ECVAM
modular approach of validation, the data set presented herein
corresponds to the first two modules, namely test definition and
within-laboratory variability [18]. Further testing of the protocol
in collaboration with OECD in additional laboratories is ongo-
ing and will provide an in-depth evaluation of transferability and
inter-laboratory variability. The assay may be used to screen for
endocrine-modulating compounds with affinity for the ER, to fur-
ther investigate equivocal results from other in vitro assays such as
transactivation assays, and itmay also be used as amechanistic tool
in order to characterize effects on the endocrine system observed
in animal studies.Whether ER binding studies can reliably predict
the outcome of corresponding in vivo screening assays such as the
uterotrophic assay remains to be explored.
Table 7
Relative binding affinities for reference and test compounds using dimethylsulfoxide as solvent.
Compound Experiment No. Relative binding affinity [%] Coefficient of variation [%]
17-Estradiol 100 –
Norethynodrel E 0.2322
F 0.2318
G 0.2094
Mean± S.D. 0.2245±0.0131 5.8
Dibutylphthalate E No affinity
F No affinity
G No affinity
Mean± S.D. – –
Genistein E 0.1324
F 0.1055
G 0.1209
Mean± S.D. 0.1196±0.0135 11.3
o,p′-DDT E 0.0702
F 0.0463
G 0.0625
Mean± S.D. 0.0596±0.0122 20.5
Corticosterone E No affinity
F No affinity
G No affinity
Mean± S.D. – –
Relative binding affinities were calculated from data given in Table 5.
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Table 8
Kd values for estrogen receptors isolated from various sources.
Estrogen receptor Expression system Receptor preparation Methodologya Kd [nM]b Reference
Full length human recombinant ER Insect cells Purified protein Charcoal 0.37 This investigation
Full length human recombinant ER Insect cells Extract Charcoal 0.22 [12]
Human ER (mainly -subtype) from MCF-7 cells – Cytosol Charcoal 0.13 [19]
Human ER (mainly -subtype) from MCF-7 cells – Cell extract No information 0.36 [20]
Full length human recombinant ER Yeast Yeast extract No information 0.35 [20]
Human recombinant ER–ligand binding domain Yeast Yeast extract No information 1.00 [20]
Human recombinant ER–ligand binding domain Bacteria Bacteria extract No information 1.49 [20]
Full length quail recombinant ER Insect cells Extract Charcoal 0.58 [12]
Full length alligator recombinant ER Insect cells Extract Charcoal 0.44 [12]
Full length salamander recombinant ER Insect cells Extract Charcoal 0.28 [12]
Full length fathead minnow recombinant ER Insect cells Extract Charcoal 0.58 [12]
Rat ER (mainly -subtype) from rat uterus, laboratory X – Cytosol Hydroxyapatite 0.15–1.18 [16]
Rat ER (mainly -subtype) from rat uterus, laboratory Y – Cytosol Hydroxyapatite 0.04–0.24 [16]
Rat ER (mainly -subtype) from rat uterus, laboratory Z – Cytosol Hydroxyapatite 0.8–1.5 [16]
a Methodology used to separate receptor-bound from unbound ligand.
b [3H]-17-estradiol was used as ligand for Kd determinations.
Table 9
Comparison of relative ER binding affinities to published data.
Compound Investigation
This investigation (full
length human
recombinant) RBA [%]
Rider et al. [12] (full
length human
recombinant) RBA [%]
Kuiper et al. [13] (full
length human
recombinant) RBA [%]
METI/CERI [14] (human
recombinant ligand
binding domain) RBA [%]
Blair et al. [15]
(rat uterus
cytosol) RBA [%]
EPA validation [16]
(rat uterus cytosol)
RBA [%]
17-Estradiol 100 100 100 100 100 100, 100, 100a
Ethynylestradiol 64.5 91.2 Not done 142 190 165, 268, 113
DES 16.8 Not done 236 88.9 400 590, 284, equivocalb
m-Hexestrol 4.46 Not done Not done 37.6 300 345, 2090, 270
Norethynodrel 0.247/0.225DMSO Not done Not done 0.282 0.204 0.135, 0.147, 0.130
Butylparaben 0.00499 Not done Not done 0.018 Not done 0.00416, 0.0105,
0.00086
Equol 1.10 Not done Not done Not done Not done 0.0812, 0.0542, 0.039
Genistein 0.199/0.120DMSO Not done 4/0.7 0.12 Not done 0.971, 4.81, 0.402
Nonylphenol 0.130 Not done 0.05 0.108 0.019–0.037 0.125, 0.101,
equivocal
o,p′-DDT 0.0689/0.0596DMSO Not done 0.01 Not done 0.001 Negative, 14,400,
negative
Dibutylphthalate No affinity Not done Not done No IC50, RBA<0.001 No affinity Not done
Corticosterone No affinity No affinity Not done Not done No affinity 0.00103, 2.04,
equivocal
For our data, solvent is ethanol, if not otherwise indicated.
a Data from three laboratories (X, Y, and Z).
b Equivocal: displacement of labeled ligand was observed, however, no characteristic binding curve was observed.
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